Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

• Genmab A/S recently reported strong Q2 2026 financial results, beating analyst expectations with earnings per share of $0.54 compared to the consensus estimate of $0.37, while also exceeding revenue forecasts with $1.16 billion in sales against an expected $1.12 billion, demonstrating robust commercial execution and profitability with a net margin of 19.08%.
• The stock is trading at a current price of $35.32, which is near its 52-week high of $35.66, reflecting strong market momentum and investor confidence in the company's trajectory, supported by a beta of 0.84 that suggests lower volatility compared to the broader market.
• Wall Street analysts maintain a positive outlook, with a consensus rating of Moderate Buy and a target price of $39.50, indicating potential upside from the current price, while recent upgrades from firms like TD Cowen and Guggenheim to Buy ratings with targets as high as $43.00 signal growing institutional support.
• Short interest in Genmab A/S has decreased significantly, dropping to 4,920,530 shares as of September 15, 2026, down from over 11 million shares in late 2025, which reduces the risk of a short squeeze and indicates that investors are increasingly confident in the company's long-term value proposition.
• Institutional investors are increasing their stakes in the company, with notable increases by funds such as Arrowstreet Capital Limited Partnership and Renaissance Technologies LLC, suggesting that sophisticated market participants are recognizing the value of Genmab A/S's antibody-based medicines and pipeline.